A5025930905- Heart Failure Treatment and Management
- Lipoproteins and Cardiovascular Health
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Cardiac Imaging and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cardiac pacing and defibrillation studies
- Cardiovascular and exercise physiology
- Cardiac Ischemia and Reperfusion
- Acute Myocardial Infarction Research
- Cardiac Fibrosis and Remodeling
- Heart Rate Variability and Autonomic Control
- Atrial Fibrillation Management and Outcomes
- Coronary Interventions and Diagnostics
- Heart rate and cardiovascular health
- Cardiac Arrest and Resuscitation
- Cardiac Valve Diseases and Treatments
- Atherosclerosis and Cardiovascular Diseases
- Viral Infections and Immunology Research
- Cardiac, Anesthesia and Surgical Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Transplantation: Methods and Outcomes
- Signaling Pathways in Disease
- Pharmaceutical Economics and Policy
Nuffield Health
2024
National Health and Medical Research Council
2024
University of Oslo
2011-2020
Oslo University Hospital
2010-2019
Rigshospitalet
2014-2018
University of Gothenburg
1990-2017
Norwegian University of Science and Technology
2001-2017
Institute of Cardiology
2017
Technical University of Munich
2017
Klinikum rechts der Isar
2017
Addendum I. SCORE charts with high-density lipoprotein-cholesterol II.Practical approach to reach low-density goal III.Inhibitors and inducers
with the European Association for Study of Diabetes (EASD).
OBJECTIVE To assess in diabetic patients with coronary heart disease (CHD) the effect of cholesterol lowering simvastatin on mortality and risk CHD other atherosclerotic events. RESEARCH DESIGN AND METHODS A post hoc subgroup analysis was carried out data from 202 4,242 nondiabetic previous myocardial infarction or angina pectoris, serum total 5.5–8.0 mmol/l, triglycerides ≤ 2.5 mmol/l who were participating Scandinavian Simvastatin Survival Study (4S). Participants 4S randomly assigned to...
The purpose of this study was the determination whether hemodynamic and pharmacologic factors influence extent severity myocardial necrosis produced by coronary occlusion. In 48 dogs, 10 to 14 epicardial leads were recorded on anterior surface left ventricle in distribution vicinity site occlusion a branch descending artery. average S-T segment elevation for each animal determined at 5-min intervals after This used as an index presence ischemic injury. number sites showing provided...
Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins theoretical risks these patients.A total of 5011 patients at least 60 years age New York Heart Association class II, III, or IV ischemic, were randomly assigned to receive 10 mg rosuvastatin placebo per day. The primary composite outcome was death cardiovascular causes, nonfatal myocardial infarction, stroke. Secondary outcomes included any...
HRONIC HEART FAILURE IS Acommon disease that has a poor prognosis and periods of incapacitating symptoms necessitating recurrent hospital admis-sions. 1,2The most common modes death are sudden or from worsening heart failure. 3The discovery the pathophysiological impor-
There is a varying hormonal activation in heart failure. To be able to evaluate this and relate it prognosis, we took blood samples at baseline after 6 weeks from 239 patients with severe failure (all New York Heart Association class IV) randomized additional treatment enalapril or placebo. In study (CONSENSUS), which has previously been reported, there was significant reduction mortality among treated enalapril. The present data show the placebo group positive relation between levels of...
AimsNiacin has potentially favourable effects on lipids, but its effect cardiovascular outcomes is uncertain. HPS2-THRIVE a large randomized trial assessing the of extended release (ER) niacin in patients at high risk vascular events.
The Scandinavian Simvastatin Survival Study (4S) randomized 4444 patients with coronary heart disease (CHD) and serum cholesterol 5.5 to 8.0 mmol/L (213 310 mg/dL) triglycerides < or =2.5 (220 simvastatin 20 40 mg placebo once daily. Over the median follow-up period of 5.4 years, one more major events (MCEs) occurred in 622 (28%) 2223 group 431 (19%) 2221 (34% risk reduction, P<.00001). produced substantial changes several lipoprotein components, which we have attempted relate beneficial...
This study was designed to develop a method for quantitative assessment of infarct size in the conscious animal based on serial changes serum creatine phosphokinase (CPK) activity. From 11 experiments which myocardial CPK injected intravenously dogs, average distribution space and fractional disappearance rate from were found be 11.4% body weight 0.48% min respectively. In other experiments, infarction produced 22 dogs by constriction left coronary artery snare activity determined at...
Background The Scandinavian Simvastatin Survival Study (4S) demonstrated pronounced reductions in mortality and major coronary events a cohort of patients with established heart disease (CHD). present study provides detailed, post hoc assessment the efficacy safety simvastatin therapy following subgroups 4S patients: those ≥65 years age, <65 women, men. Methods Results 4444 CHD included 827 women 1021 age. Total cholesterol at baseline was 5.5 to 8.0 mmol/L triglycerides ≤2.5 mmol/L....
Long-term treatment with timolol in patients ages 65--75 years who survived myocardial infarction was related to a significant reduction, compared placebo, overall mortality (p less than 0.05), total cardiac death 0.01), sudden 0.05) and reinfarction 0.01). The analyses were based on 732 (384 taking placebo 348 timolol) from cohort of 1884 the Norwegian multicenter study. dosage 10 mg twice daily followed for 12--33 months (mean 17 months). There 83 deaths group 52 group, reduction 35.5%. 69...
<h3>Background</h3> Patients with diabetes mellitus (DM) have a marked increase in coronary heart disease (CHD) events relative to those without DM. In previous report from the Scandinavian Simvastatin Survival Study using clinical case definition of DM (n = 202), simvastatin-treated patients had significantly fewer CHD compared placebo-treated control subjects. <h3>Objective</h3> To examine effect simvastatin therapy on and impaired fasting glucose levels. <h3>Methods</h3> Using 1997...
The risk of sudden death has changed over time among patients with symptomatic heart failure and reduced ejection fraction the sequential introduction medications including angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, mineralocorticoid-receptor antagonists. We sought to examine this trend in detail.We analyzed data from 40,195 who had were enrolled any 12 clinical trials spanning period 1995 through 2014. Patients an implantable...